Where is CASI Pharmaceuticals headquartered?

CASI Pharmaceuticals is recorded with headquarters in San Francisco, USA in NovaPharmaNews public regulatory and sponsor datasets.

Is CASI Pharmaceuticals publicly traded?

Yes — CASI Pharmaceuticals is listed as a public company with ticker CASIF on NYSE in SEC EDGAR-derived records.

What drugs are associated with CASI Pharmaceuticals?

We link 1 drug profile(s) where CASI Pharmaceuticals appears as originator or marketer in FDA or regional approval metadata.

What clinical trials is CASI Pharmaceuticals sponsoring?

CASI Pharmaceuticals is linked to 22 pipeline program(s) sourced from ClinicalTrials.gov and EU CTIS where sponsor names match.

What patents list CASI Pharmaceuticals as applicant?

2 USPTO PatentsView record(s) name CASI Pharmaceuticals or a normalized variant as applicant.

What pipeline phases does CASI Pharmaceuticals have in our database?

Phase distribution from linked programs: phase 2: 16, phase 1: 5, approved: 1.

How many US-approved drugs are linked to CASI Pharmaceuticals?

1 linked drug profile(s) include US approval status in openFDA-derived metadata.

Where does NovaPharmaNews source data on CASI Pharmaceuticals?

Profiles combine SEC EDGAR (US issuers), FDA openFDA, EMA medicines data, ClinicalTrials.gov, EU CTIS, USPTO PatentsView, and regional PBS/PMDA/NMPA feeds. See /about/data-sources.

Is CASI Pharmaceuticals data investment advice?

No. This profile is compiled from public regulatory records for professional reference only, not investment or medical advice.

Is CASI Pharmaceuticals data investment advice?

No. This profile is compiled from public regulatory records for professional reference only, not investment or medical advice.

CASI Pharmaceuticals Pharmaceuticals Company Profile

Name: CASI Pharmaceuticals intelligence dataset
Creator: NovaPharmaNews
License: https://www.sec.gov/edgar.shtml

Company details

Status: Public
HQ: 601 Gateway Blvd, San Francisco, CA 94080, US
Employees: 44
Programs: 22
Drugs: 11
Patents: 2

Official website ↗ All projects Drug pipeline Patents News & analysis

Quick answer

CASI Pharmaceuticals is a pharma organization headquartered in San Francisco, USA. It trades on NYSE under ticker CASIF. Primary therapeutic focus areas include Multiple Myeloma, Ovarian Cancer, Advanced Cancer, Recurrent Glioblastoma Multiforme, Relapsed Multiple Myeloma. NovaPharmaNews links 22 clinical program(s), 1 drug profile(s), and 2 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline phase mix: phase 2 (16), phase 1 (5), approved (1).

Company snapshot

CASI Pharmaceuticals, Inc. (NASDAQ: CASI), a clinical-stage biopharmaceutical company focused on developing innovative therapies for patients with organ transplant rejection and autoimmune diseases, today announced FDA clearance of an IND application for CID-103, an anti-CD38 monoclonal antibody in adults with active and chronic active renal allograft antibody mediated rejection (AMR). The Phase 1

1 approved product(s) across US/EU regulatory metadata.
22 active pipeline program(s) linked via ClinicalTrials.gov.
2 US patent(s) indexed to this assignee profile.

Public regulatory, clinical, patent, and corporate records for CASI Pharmaceuticals. Not investment advice.

Top assets

View drugs (11) View projects (22)

Lead pipeline drugs

bevacizumab
approved
carisoprodol
approved
chloride
Marketed / approved
estradiol
approved

Active clinical programs

2-methoxyestradiol Relapsed Multiple Myeloma
Phase 2
CID-103 Chronic Immune Thrombocytopenia
Phase 2
ENMD-2076 Ovarian Cancer
Phase 2
ENMD-2076 Advanced Adult Hepatocellular Carcinoma
Phase 2

Momentum

Proprietary activity score for CASI Pharmaceuticals.

1 active signal

20 /100 +0 vs 30 days ago

Signal breakdown

Clinical trials 24 30d
Nova articles 0 30d
Patents filed 0 30d
FDA actions 0 30d
SEC filings 0 30d
Conference presentations 0 90d
Pipeline advances 0 30d

Competitor landscape

Therapeutic-area overlap peers from registry and pipeline signals.

Peer + 0 momentum

Chinese Academy of

TA overlap score 40
Peer + 0 momentum

First People's Hospital

TA overlap score 40
Peer + 0 momentum

MEREO BIOPHARMA GROUP

TA overlap score 29.4
Peer + 0 momentum

Alaunos Therapeutics

TA overlap score 26.8
Peer + 0 momentum

Samsung Bioepis

TA overlap score 24.8
Peer + 0 momentum

Oncolytics Biotech

TA overlap score 24.6
Peer + 0 momentum

CNS Pharmaceuticals

TA overlap score 24.2
Peer + 0 momentum

Prime Medicine

TA overlap score 23.4
Peer + 0 momentum

Zentalis Pharmaceuticals

TA overlap score 22.8
Peer + 0 momentum

Prelude Therapeutics

TA overlap score 22.6

Recent activity

Latest pipeline, patent, and corporate events for CASI Pharmaceuticals.

Jun 8, 2026 Clinical update
ME-CLN-002 — Phase 2
Jun 8, 2026 Clinical update
melphalan hydrochloride for injection — Approved
Jun 8, 2026 Clinical update
2-methoxyestradiol — Phase 2
Jun 5, 2026 Clinical update
recombinant human Angiostatin protein — Phase 2
Jun 5, 2026 Clinical update
MKC-1 — Phase 1

View all clinical trial activity →

Quick answers

Common questions about this sponsor — for analysts and search.

What is CASI Pharmaceuticals?

CASI Pharmaceuticals is a pharma organization headquartered in San Francisco, USA. It trades on NYSE under ticker CASIF. Primary therapeutic focus areas include Multiple Myeloma, Ovarian Cancer, Advanced Cancer, Recurrent Glioblastoma Multiforme, Relapsed Multiple Myeloma. NovaPh
Is CASI Pharmaceuticals publicly traded?

Yes. CASI Pharmaceuticals is listed with ticker CASIF on NYSE per SEC EDGAR records linked on this profile.
What drugs does CASI Pharmaceuticals develop or market?

We link 11 drug profile(s) where CASI Pharmaceuticals is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/casi-pharmaceuticals#company-drugs.
What are the latest developments for CASI Pharmaceuticals?

In the last 12 months our linked public records show 22 trial program update(s) and 0 US patent grant(s) tied to this profile.
What therapeutic areas does CASI Pharmaceuticals focus on?

CASI Pharmaceuticals focuses on Multiple Myeloma, Ovarian Cancer, Advanced Cancer based on our analysis of their pipeline programs and drug development activities.

Therapeutic focus

Therapeutic area distribution

Pipeline concentration by therapeutic area from linked clinical programs.

Programs by therapeutic area

Others

Oncology

Infectious Disease